Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether his Department plans to take steps to ensure Enhertu remains available on the NHS.

Decisions on whether new medicines should be routinely funded by the National Health Service in England are made on the basis of recommendations from the National Institute for Health and Care Excellence (NICE) following an evaluation of a treatment’s costs and benefits. These are very difficult decisions to make, and it is important that they are made independently and on the basis of the available evidence.

NICE has recommended Enhertu (trastuzumab deruxtecan) for use through the Cancer Drugs Fund for the treatment of HER2-positive unresectable or metastatic breast cancer after one or more anti-HER 2 treatments and for treating HER2-positive unresectable or metastatic breast cancer after two or more anti-HER2 therapies. Enhertu is now funded for eligible patients in England through the Cancer Drugs Fund in line with NICE’s recommendations. NICE will consider the evidence collected on the use of Enhertu through the Cancer Drugs Fund into account in making recommendations for the NHS on whether it should be routinely funded by the NHS.

NICE published guidance in July 2024 on the use of Enhertu for the treatment of HER-2 low metastatic and unresectable breast cancer and was unfortunately unable to recommend it for routine NHS funding.